BioSyent Inc. (CVE:RX – Get Free Report) shares crossed above its 50 day moving average during trading on Tuesday . The stock has a 50 day moving average of C$14.19 and traded as high as C$14.70. BioSyent shares last traded at C$14.70, with a volume of 3,046 shares.
BioSyent Price Performance
The firm has a market capitalization of C$166.47 million, a price-to-earnings ratio of 18.74 and a beta of 0.99. The company has a quick ratio of 6.91, a current ratio of 1.89 and a debt-to-equity ratio of 11.66. The company’s fifty day moving average is C$14.19 and its two-hundred day moving average is C$14.33.
Insider Buying and Selling at BioSyent
In other news, Director Seyed Ahmad Ashrafi sold 1,884 shares of the firm’s stock in a transaction on Tuesday, June 30th. The stock was sold at an average price of C$14.65, for a total value of C$27,600.60. Following the transaction, the director directly owned 37,261 shares in the company, valued at C$545,873.65. This trade represents a 4.81% decrease in their position. Over the last 90 days, insiders sold 4,358 shares of company stock valued at $63,132. Corporate insiders own 33.65% of the company’s stock.
BioSyent Company Profile
BioSyent Inc, together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia. It offers Tibella, a hormone replacement therapy consisting of tibolone; Inofolic, a natural health product to address polycystic ovarian syndrome symptoms; RepaGyn, a vaginal suppository for the healing of the vaginal mucosa, as well as for the treatment of vaginal dryness caused by aging, menopause, stress, and chemotherapy; and Gelclair, a gel formulated to aid the pain or oral mucositis.
See Also
- Five stocks we like better than BioSyent
- Premium Retail’s Stress Test Is Separating Winners From Losers
- D-Wave Quantum or a Quantum ETF: Which Is the Better Bet?
- GE Vernova Just Sent a Mixed AI Signal to Investors
- Alphabet Crushed Earnings, But One Number Spooked the Market
Receive News & Ratings for BioSyent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioSyent and related companies with MarketBeat.com's FREE daily email newsletter.
